421 Results
Sort By:
Published on January 29, 2025
A team from Duke has used transcriptomic analysis to identify differential alternative RNA splicing events (ARSs) between Black and White prostate cancer (PCa) patients, with the hope of creating a genomic landscape of this disease to create better precision medicines for it. The study appeared in npj Precision Oncology and…
Published on January 29, 2025
Research led by Vanderbilt University shows that disease-causing variants of the WNT9B gene increase prostate cancer risk if inherited. As reported in JCO Precision Oncology, the researchers tested whether the link between WNT9B and prostate cancer risk was widespread by testing samples from four large biobanks in Europe and found…
Published on January 21, 2025
Gene classifier (GC) tests for prostate cancer (PCa) may influence treatment decisions despite lack of evidence for long-term outcomes. A systematic review of genomic classifier tests confirms they may influence treatment decisions for patients with localized prostate cancer, but without giving optimal results. There is a need for better data…
Published on January 6, 2025
Research led by the University of California, Los Angeles, shows that conventional imaging may not be able to correctly assess prostate cancer patients whose cancer has metastasized and spread to other areas of the body. The team looked at a group of people with prostate cancer who were previously classed…
Published on November 22, 2024
Researchers have made a major breakthrough in understanding how advanced prostate cancer develops resistance to poly(ADP-ribose) polymerase inhibitors (PARPi), a critical class of drugs for treating metastatic castration-resistant prostate cancer (mCRPC). A study published in Cancer Cell reveals the genetic adaptations tumors use to evade these therapies, offering insights that…
Published on November 20, 2024
Researchers at Weill Cornell Medicine have uncovered a surprising role for the enzyme EZH2 in driving aggressive tumor growth in prostate cancers resistant to treatment. Published in Nature Communications, the study reveals that EZH2, regulated by the protein kinase PKCλ/ι, contributes to tumor progression by evading proteasomal degradation. These findings…
Published on November 13, 2024
A recent study by researchers at the UCLA Health Jonsson Comprehensive Cancer Center has shown that a combination of the immune checkpoint inhibitor pembrolizumab and chemotherapy may improve survival outcomes for patients with small cell bladder cancer (SCBC) and small cell/neuroendocrine prostate cancer (NEPC). The research, published in Cell Reports…
Published on November 6, 2024
Men with treatment-emergent neuroendocrine prostate cancer (t-NEPC) could benefit from human epidermal growth factor receptor (HER)2 testing and treatment with trastuzumab deruxtecan (T-DXd), suggest researchers from the Washington DC Veterans Affairs Medical Center and The George Washington University School of Medicine. They report in the Annals of Internal Medicine, the…
Published on October 30, 2024
Researchers led by CSHL professor Lloyd Trotman’s lab have found that the pro-oxidant supplement menadione slows prostate cancer progression in mice. The supplement is a precursor to vitamin K, commonly found in leafy greens. The findings are published in Science in an article titled, “Dietary pro-oxidant therapy by a vitamin…
Published on October 23, 2024
A healthy diet may reduce the chance of low risk prostate cancer progressing in men undergoing active surveillance, according to a team led by researchers at Johns Hopkins Medicine. This finding further supports the idea that men with lower risk prostate cancer can be carefully monitored in lieu of undergoing…
Published on October 9, 2024
A blood test that measures the number of circulating tumor cells (CTCs) at the time of metastatic prostate cancer diagnosis can predict treatment response, disease progression, and overall survival, regardless of subsequent therapies over time, shows a study led by University of Southern California (USC) researchers. The test could be…
Published on October 3, 2024
The question of whose DNA or RNA was used to develop a complex genetic test, such as those that use AI to identify patterns of genetic variants or gene expression levels, is fundamental to its applicability—the people most like those who were used to develop the test are the most…
Published on September 25, 2024
A preclinical mouse model that uses CRISPR reveals how prostate cancer spreads or metastasizes. The model developed by a team of researchers led by Weill Cornell Medicine demonstrates the routes prostate cancer metastatic cells take as they travel through the body, and could lead to more effective treatments. Their findings…
Published on September 16, 2024
Men with a specific prostate cancer mutation could benefit from treatment with dual immunotherapy with immune checkpoint inhibitors. Writing in the Annals of Oncology, Niven Mehra, MD, PhD, an oncologist and researcher based at the Radboud University Medical Center in the Netherlands, and colleagues report that men whose tumor had…
Published on September 11, 2024
New research from the University of Michigan has shed light on a pivotal protein, NSD2, and its role in promoting prostate cancer. NSD2 is a histone methyltransferase, a protein responsible for modifying histones—proteins around which DNA is wrapped. This modification influences the accessibility of DNA, ultimately affecting gene expression. In…